Anoop Shajith, Misra Anoop, Bhatt Surya Prakash, Gulati Seema, Pandey Ravindra Mohan, Mahajan Harsh
Centre of Nutrition & Metabolic Research (C-NET), National Diabetes, Obesity and Cholesterol Foundation (N-DOC), New Delhi, India.
Diabetes Foundation (India), Safdarjung Development Area, New Delhi, India.
BMJ Open Diabetes Res Care. 2017 Nov 6;5(1):e000393. doi: 10.1136/bmjdrc-2017-000393. eCollection 2017.
To evaluate circulating plasma dipeptidyl peptidase-4 (DPP4) levels in non-obese Asian Indians with type 2 diabetes mellitus (T2DM), and to correlate these with metabolic profile and measures of anthropometry, skinfolds, abdominal adipose tissue depots, pancreatic volume, and liver span.
Non-obese (body mass index (BMI) <25 kg/m) patients with T2DM (cases, =93), diagnosed within 1 year from recruitment, on metformin therapy and BMI-matched, and non-diabetic subjects (controls, n=40) were compared. Measurements of blood glucose, glycosylated hemoglobin, plasma insulin levels, lipid profile, hepatic transaminases and plasma DPP4 levels, and quantification of abdominal fat depots, pancreatic volume and liver span (MRI scan), were done.
Significantly higher (<0.001) circulating plasma DPP4 levels were observed in cases as compared to controls. Specifically, in patients with T2DM with non-alcoholic fatty liver disease (NAFLD) (=48), the mean plasma DPP4 level (52.6±27.8 ng/mL) was significantly higher (<0.05) as compared with those without NAFLD (=43; 47±28.3 ng/mL). Significant positive correlation was observed for circulating plasma DPP4 levels with waist-to-hip ratio, total intra-abdominal adipose volume, and liver span. Fasting serum insulin, low-density lipoprotein cholesterol (LDL-C), triceps skinfolds, total intra-abdominal adipose tissue volume and presence of T2DM were significant determinants of circulating plasma DPP4 levels.
Non-obese Asian Indian patients with T2DM and on metformin therapy have significantly higher circulating plasma DPP4 levels as compared to non-obese non-diabetic controls, and these levels correlate with fasting insulin and LDL-C levels, upper limb subcutaneous adipose tissue, intra-abdominal adiposity and presence of diabetes.
评估非肥胖亚洲印度裔2型糖尿病(T2DM)患者循环血浆二肽基肽酶-4(DPP4)水平,并将其与代谢谱、人体测量指标、皮褶厚度、腹部脂肪储存、胰腺体积和肝径进行关联分析。
比较招募后1年内确诊、正在接受二甲双胍治疗且体重指数(BMI)匹配的非肥胖(BMI<25kg/m²)T2DM患者(病例组,n=93)和非糖尿病受试者(对照组,n=40)。检测血糖、糖化血红蛋白、血浆胰岛素水平、血脂谱、肝转氨酶和血浆DPP4水平,并对腹部脂肪储存、胰腺体积和肝径进行定量分析(磁共振成像扫描)。
与对照组相比,病例组循环血浆DPP4水平显著升高(P<0.001)。具体而言,在患有非酒精性脂肪性肝病(NAFLD)的T2DM患者(n=48)中,平均血浆DPP4水平(52.6±27.8ng/mL)显著高于未患NAFLD的患者(n=43;47±28.3ng/mL,P<0.05)。循环血浆DPP4水平与腰臀比、腹内脂肪总体积和肝径呈显著正相关。空腹血清胰岛素、低密度脂蛋白胆固醇(LDL-C)、肱三头肌皮褶厚度、腹内脂肪总体积和T2DM的存在是循环血浆DPP4水平的显著决定因素。
与非肥胖非糖尿病对照组相比,接受二甲双胍治疗的非肥胖亚洲印度裔T2DM患者循环血浆DPP4水平显著升高,且这些水平与空腹胰岛素和LDL-C水平、上肢皮下脂肪组织、腹内肥胖及糖尿病的存在相关。